KRAS and neoplasm: Combination therapies with MET TKIs and trametinib—an inhibitor of the MAPK pathway via the inhibition of MEK 1/2 activity—have shown a greater reduction of tumor growth in vitro than either therapy alone and suggest the utility of such therapeutic strategies for patients with concurrent MET and KRAS mutations [135,136]; however, tailoring this treatment approach for clinical use will require further investigation to determine optimal dosage for the patient to exhibit a response and lessen the severity of side effects [136].